

CE COMMUNIQUÉ NE DOIT PAS ÊTRE DIFFUSÉ, PUBLIÉ OU DISTRIBUÉ, DIRECTEMENT OU INDIRECTEMENT, AUX ÉTATS-UNIS, AU CANADA, EN AUSTRALIE OU AU JAPON.



## COMMUNIQUÉ DE PRESSE

Date 3 avril 2017  
Contact Investor Relations: Felix Burkhard, CFO, Groupe Galenica  
Media Relations: Christina Hertig, Responsable de la Communication, Groupe Galenica

Sujet IPO de Galenica Santé: Galenica annonce une fourchette de prix réduite

### **IPO de Galenica Santé: Galenica annonce une fourchette de prix réduite et augmente le volume de l'IPO**

Le Groupe Galenica a annoncé aujourd'hui une fourchette de prix réduite entre CHF 37.00 et CHF 39.00 par action (avant CHF 31.00 à CHF 39.00), impliquant une capitalisation boursière totale de Galenica Santé d'environ CHF 1'850 millions à CHF 1'950 millions.

En raison d'une forte demande de la part d'un large éventail d'investisseurs, le Groupe Galenica a décidé d'augmenter le volume de l'offre de base de 4'891'300 actions et l'option de surallocation de 733'700 actions, respectivement. L'IPO élargie porte sur 42'391'300 actions nominatives ordinaires ainsi qu'une option de surallocation de 6'358'700 actions au maximum.

A condition que l'option de surallocation soit entièrement exercée, le flottant de Galenica Santé (Free Float) devrait représenter 97.5% des actions (environ 85% avant l'exercice de l'option de surallocation). Après la cotation et partant du principe que l'option de surallocation est entièrement exercée, le Groupe Galenica ne détiendra plus d'actions dans Galenica Santé à l'avenir.

Les actions restantes, soit 2.5% du capital-actions de Galenica Santé, seront réservées pour l'échange des actions du Groupe Galenica en actions Galenica Santé pour les collaborateurs habilités de Galenica Santé.

La période de bookbuilding a été raccourcie d'un jour et durera jusqu'au 5 avril 2017, 12h00 HAEC pour les ordres retail et private banking et 18h00 HAEC pour les investisseurs institutionnels, respectivement. Le premier jour de négoce reste le vendredi 7 avril 2017.

Toute décision de placement comporte des risques et doit reposer sur le mémorandum d'offre, disponible auprès de Credit Suisse SA, Zurich, Suisse (e-mail: [equity.prospectus@credit-suisse.com](mailto:equity.prospectus@credit-suisse.com)) et d'UBS SA, Zurich, Suisse (numéro de téléphone: +41 44 239 47 03; numéro de fax: +41 44 239 69 14; e-mail: [swiss-prospectus@ubs.com](mailto:swiss-prospectus@ubs.com)).

#### **Pour tout renseignement complémentaire:**

##### **Media Relations:**

Christina Hertig, Responsable de la Communication  
Tél. +41 58 852 85 17  
E-mail: [media@galenica.com](mailto:media@galenica.com)

##### **Investor Relations:**

Felix Burkhard, CFO  
Tél. +41 58 852 85 29  
E-mail: [investors@galenica.com](mailto:investors@galenica.com)

*Galenica est un groupe d'entreprises diversifié du marché de la santé qui exerce notamment ses activités dans le développement, la production et la distribution de médicaments, la gestion de pharmacies, les services logistiques ainsi que dans l'exploitation de banques de données et de réseaux. Avec ses deux entités Vifor Pharma et Galenica Santé, le Groupe Galenica occupe une position de leader dans toutes ses activités clés. Il réalise une grande partie de ses bénéfices sur les marchés internationaux. Galenica est cotée à la Bourse suisse (SIX Swiss Exchange, GALN, numéro de valeur 1'553'646).*

*Vous trouverez de plus amples informations sur le Groupe Galenica en consultant [www.galenica.com](http://www.galenica.com).*

Galenica SA  
Case postale · Untermattweg 8 · CH-3001 Berne  
Téléphone +41 58 852 85 17 · Fax +41 58 852 85 58  
[media@galenica.com](mailto:media@galenica.com) · [www.galenica.com](http://www.galenica.com)

Date 3 avril 2017  
Page 2/2  
Sujet IPO de Galenica Santé: Galenica annonce une fourchette de prix réduite

## **Disclaimer**

*This document is not an offer to sell or a solicitation of offers to purchase or subscribe for shares. This document is not a prospectus within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus as defined in the listing rules of the SIX Swiss Exchange AG or a prospectus under any other applicable laws. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law. The information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy, in any jurisdiction in which such offer or solicitation would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any jurisdiction. A decision to invest in securities of Galenica Santé AG (the "Company") should be based exclusively on the issue and listing prospectus to be published by the Company for such purpose.*

*This document and the information contained herein are for information purposes only and do not constitute a prospectus or an offer to sell, or a solicitation of an offer to buy, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or pursuant to an available exemption from registration under the Securities Act. Neither Galenica Santé AG (the "Company") nor its shareholder intends to register any securities referred to herein in the United States.*

*The information contained herein does not constitute an offer of securities to the public in the United Kingdom. No prospectus offering securities to the public will be published in the United Kingdom. This document is being communicated only to (i) persons who are outside the U.K.; (ii) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (iii) high net worth companies, unincorporated associations and other bodies who fall within article 49(2)(a) to (d) of the Order (all such persons together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This document should not be published, reproduced, distributed or otherwise made available, in whole or in part, to any other person without the prior consent of the Company.*

*Any offer of securities to the public that may be deemed to be made pursuant to this communication in any member state of the European Economic Area (each an "EEA Member State") that has implemented Directive 2003/71/EC (together with the 2010 PD Amending Directive 2010/73/EU, including any applicable implementing measures in any Member State, the "Prospectus Directive") is only addressed to qualified investors in that Member State within the meaning of the Prospectus Directive.*

*The Joint Bookrunners and Co-Lead Managers are acting exclusively for the Company and no-one else in connection with the Offering. They will not regard any other person as their respective clients in relation to the Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, nor for providing advice in relation to the Offering, the contents of this announcement or any transaction, arrangement or other matter referred to herein.*

*This document contains forward-looking statements. These statements are based on the current views, expectations, assumptions and information of the management of the Company. Forward-looking statements should not be construed as a promise of future results and developments and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those described in such statements due to a number of factors. The Company does not assume any obligations to update any forward-looking statements.*